Print Page  Close Window

Investor Relations
Corporate Profile

We are Zogenix.

Zogenix is committed to developing therapies that address specific clinical needs for people living with CNS and pain-related conditions who need innovative treatment alternatives to help them return to normal daily functioning.

A significant number of patients are not being effectively treated, despite the availability of current therapies. These patients deserve access to safe and effective treatments. Zogenix is committed to ensuring the safe and appropriate use of our products ... More >>

Latest PresentationsMore >>
Title
Download Documentation Zogenix June 2014 Investor Presentation
Get help downloading or viewing the above file types
Stock Quote
ZGNX (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$1.35
Change (%) Stock is Up 0.07 (5.47%)
Volume2,092,946
Data as of 08/29/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
DateTitle 
08/05/14Zogenix Reports Second Quarter 2014 Financial Results
Conference Call and Webcast Today, August 5, at 4:30 p.m. ET Recent Business Highlights Provided updated timeline for abuse deterrent formulations of Zohydro® ER (hydrocodone bitartrate) Extended-Release Capsules, CII, with sNDA for first candidate expected to be filed by October, with potential approval in early 2015 Completed sale of SUMAVEL® DosePro® migraine therapy business to Endo International plc for $89.6 million in cash, milestone payments of up to $20 million, and ap... 
Printer Friendly Version
08/01/14Zogenix Announces Departure of Chief Commercial Officer, Scott Shively
SAN DIEGO, Aug. 1, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central nervous system disorders, today announced that Scott Shively has resigned as Chief Commercial Officer in order to pursue another opportunity. In the interim, Roger Hawley, the Company's Chief Executive Officer, will assume the duties and responsibilities of the Chief Commercial Officer and lead the conti... 
Printer Friendly Version
07/22/14Zogenix Announces Conference Call and Webcast to Present Second Quarter 2014 Financial Results
Conference Call Scheduled for August 5, 2014 at 4:30 pm ET SAN DIEGO, July 22, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, today announced it will release financial results for the second quarter ended June 30, 2014, after the market closes on Tuesday, August 5, 2014, and will hold a conference call on this day at 4:30 p.m. ET (1:30 p.m. PT), t... 
Printer Friendly Version
07/17/14Zogenix Announces Appointment of David Brushwood, J.D., R.Ph., to External Safe Use Board
Board Commends Comprehensive Surveillance Program, Educational Efforts for Zohydro(R) ER SAN DIEGO, July 17, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central nervous system disorders, today announced that David Brushwood, J.D., R.Ph., recently-retired Professor Emeritus of Pharmaceutical Outcomes and Policy at the University of Florida, College of Pharmacy, has joined t... 
Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.